Augurix, ETHZ and University of Zurich receive funding from Swiss Government to initiate research on Inflammatory Bowel Disease programme
21 Mar 2013
Augurix Diagnostics, together with the ETH Zurich and the University Hospital of Zurich are pleased to announce that they have received funding from the Swiss Government’s Commission for Innovation (CTI) for a joint development collaboration.
The project involves the Drug Formulation & Delivery laboratory at the ETH Zurich, directed by Professor Jean-Christophe Leroux, Professor Gerhard Rogler from the Division of Gastroenterology and Hepatology at the University Hospital of Zurich, and Dr Michele Bernasconi from the University Children’s Hospital Zurich.
The 18 months collaboration is the first phase of a project aiming at developing a new oral contrast agent dedicated to the early stratification of patients suffering from pre-fibrotic Inflammatory Bowel Diseases (IBD). Specific biomarkers will be bound to an orally-tolerated, non-toxic biopolymer structure. Such a tailored IBD probe will be more patient-friendly, making the endoscopic examination less labor intensive. It will also open new horizons in terms of diagnosis and timely treatments, tapping into a market evaluated to more than 2billion Euros.
Get the press release